Bharat Biotech gets DGCI nod for intranasal Covid booster doses | Latest News India - Hindustan Times
close_game
close_game

Bharat Biotech gets DGCI nod for intranasal Covid booster doses

By, New Delhi
Jan 28, 2022 02:27 PM IST

The trials will be held at nice different sites.

The Drugs Controller General of India (DCGI) on Friday gave its permission to Bharat Biotech for conducting trials of intranasal booster doses against the coronavirus disease (Covid-19). 

Representational image.
Representational image.

According to an input from news agency ANI, the trials will be held at nice different sites.

Unlock exclusive access to the latest news on India's general elections, only on the HT App. Download Now! Download Now!

A day ago, the Hyderabad-based pharmaceutical company's anti-Covid vaccine Covaxin was recently granted regular market approval for use in the adult population subject to certain conditions. A similar nod has also been given to Serum Institute of India's Covishield. Both the widely used vaccines in the country's fight against the pandemic had so far been grante restricted use in emergency situations.

Tell us what your First Vote will stand for in a short video & get a chance to be featured on HT’s social media handles. Click here to know more!

Get Current Updates on India News, Elections 2024, Lok Sabha Election 2024 Live, Election 2024 Date, Weather Today along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Wednesday, May 22, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On